The Pediatric Acute Leukemia/European Pediatric Acute Leukemia (PedAL/EUPAL) project, a collaborative research initiative as an offspring of the ACCELERATE AML platform meeting in 2019 (Pearson et al., 2020), and supported by the Leukemia Lymphoma Society, is actively engaged with multiple biopharma companies to develop and conduct studies with menin inhibitors focused on pediatric acute leukemias (ACCELERATE virtual meeting on Menin inhibitors, 2022). Here, MEN1 is linked to acute leukemia.